Protocolo diagnóstico de las toxicodermias

  1. Burgos Blasco, P. 1
  2. Melián Olivera, A. 1
  3. Selda Enríquez, G. 1
  4. Jaén Olasolo, P. 1
  1. 1 Servicio de Dermatología. Hospital Universitario Ramón y Cajal. IRYCIS. Madrid. España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Any de publicació: 2022

Títol de l'exemplar: Enfermedades de la piel (II)

Sèrie: 13

Número: 48

Pàgines: 2825-2829

Tipus: Article

DOI: 10.1016/J.MED.2022.02.006 DIALNET GOOGLE SCHOLAR

Altres publicacions en: Medicine: Programa de Formación Médica Continuada Acreditado

Objectius de Desenvolupament Sostenible

Resum

The skin is one of the main targets through which adverse drug effects manifest. The incidence of these reactions is rising due to the progressive availability of a greater number of drugs. Clinically, these drugs can trigger any type of skin reaction, from the mildest, such as nonspecific morbilliform exanthematous drug eruption, to severe reactions such as toxic epidermal necrolysis. When faced with toxicoderma, clinical suspicion is fundamental to making an early diagnosis and identification of the drug suspected to be responsible for the reaction in order to suspend it

Referències bibliogràfiques

  • Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137(6):765-70.
  • Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Allergol Select. 2017;1(1):96-108.
  • Drago F, Cogorno L, Agnoletti AF, Ciccarese G, Parodi A. A retrospective study of cutaneous drug reactions in an outpatient population. Int J Clin Pharm. 2015;37(5):739-43.
  • Peroni A, Colato C, Schena D, Girolomoni G. Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part I. Cutaneous diseases. J Am Acad Dermatol. 2010;62(4):541-55.
  • Crisafulli G, Franceschini F, Caimmi S, Bottau P, Liotti L, Saretta F. Mild cutaneous reactions to drugs. Acta Biomed. 2019;90(3-S):36-43.
  • Duong TA, Valeyrie Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet. 2017; 390(10106): 1996-2011.
  • Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol. 2015;73(5):843-8.
  • Cabañas R, Ramírez E, Sendagorta E, Alamar R, Barranco R, Blanca López N. Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS syndrome. J Investig Allergol Clin Immunol. 2020;30(4):229-53.
  • Zhang AJ, Nygaard RM, Endorf FW, Hylwa SA. Stevens Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience. Int J Dermatol. 2019;58(9):1069-7
Fuente de los datos: Dialnet